THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F20%3A00116168" target="_blank" >RIV/00216224:14110/20:00116168 - isvavai.cz</a>
Result on the web
<a href="http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf" target="_blank" >http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.31925/farmacia.2020.3.25" target="_blank" >10.31925/farmacia.2020.3.25</a>
Alternative languages
Result language
angličtina
Original language name
THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS
Original language description
Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
FARMACIA
ISSN
0014-8237
e-ISSN
2065-0019
Volume of the periodical
68
Issue of the periodical within the volume
3
Country of publishing house
RO - ROMANIA
Number of pages
7
Pages from-to
572-578
UT code for WoS article
000543326400025
EID of the result in the Scopus database
2-s2.0-85086844807